PASG Q4 2024 Earnings — Passage Bio, Inc. Revenue & Financial Results | Market Cap Arena

PASGPassage Bio, Inc.

$29M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$719,000

Operating Income

-$14M

Net Income

-$13M

EPS (Diluted)

$-4.10

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$102M

Total Liabilities

$41M

Stockholders' Equity

$61M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$719,000	$0	—
Operating Income	-$14M	-$18M	+22.6%
Net Income	-$13M	-$17M	+24.1%